The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2019 | Final analysis of ELOQUENT-2: QoL in RRMM with elotuzumab plus Ld
Ravi Vij, MD, MBA, Washington University School of Medicine, Saint Louis, MO, outlines the final analysis of patient-reported outcomes data from ELOQUENT-2 study (NCT01239797) of elotuzumab plus lenalidomide/dexamethasone (Ld) in patients with relapsed/refractory (R/R) multiple myeloma (MM). This final analysis confirms that the efficacy benefits observed with addition of elotuzumab to Ld in patients with R/R MM were achieved without negatively affecting health-related quality of life compared with Ld. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
